keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/29774087/severity-of-gastric-mucosal-atrophy-affects-the-healing-speed-of-post-endoscopic-submucosal-dissection-ulcers
#1
Taketo Otsuka, Mitsushige Sugimoto, Hiromitsu Ban, Toshiro Nakata, Masaki Murata, Atsushi Nishida, Osamu Inatomi, Shigeki Bamba, Akira Andoh
AIM: To investigate factors associated with the healing of endoscopic submucosal dissection (ESD)-induced ulcers. METHODS: We enrolled 132 patients with gastric tumors scheduled for ESD. Following ESD, patients were treated with daily lansoprazole 30 mg or vonoprazan 20 mg. Ulcer size was endoscopically measured on the day after ESD and at 4 and 8 wk. The gastric mucosa was endoscopically graded according to the Kyoto gastritis scoring system. We assessed the number of patients with and without a 90% reduction in ulcer area at 4 wk post-ESD and scar formation at 8 wk, and looked for risk factors for slower healing...
May 16, 2018: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29767036/response-to-comment-on-first-line-helicobacter-pylori-eradication-with-vonoprazan-clarithromycin-and-metronidazole-in-patients-allergic-to-penicillin
#2
COMMENT
Soichiro Sue, Nobumi Suzuki, Wataru Shibata, Tomohiko Sasaki, Hiroaki Yamada, Hiroaki Kaneko, Toshihide Tamura, Tomohiro Ishii, Masaaki Kondo, Shin Maeda
No abstract text is available yet for this article.
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29739175/potent-potassium-competitive-acid-blockers-a-new-era-for-the-treatment-of-acid-related-diseases
#3
REVIEW
Tadayuki Oshima, Hiroto Miwa
Conventional proton pump inhibitors (PPIs) are used as a first-line therapy to treat acid-related diseases worldwide. However, they have a number of limitations including slow onset of action, influence by cytochrome P450 polymorphisms, unsatisfactory effects at night, and instability in acidic conditions. Alternative formulations of conventional PPIs have been developed to overcome these problems; however, these drugs have only introduced small advantages for controlling acid secretion compared to conventional PPIs...
May 9, 2018: Journal of Neurogastroenterology and Motility
https://www.readbyqxmd.com/read/29676395/comment-on-first-line-helicobacter-pylori-eradication-with-vonoprazan-clarithromycin-and-metronidazole-in-patients-allergic-to-penicillin
#4
COMMENT
Negin Kashani, Amin Talebi Bezmin Abadi
No abstract text is available yet for this article.
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29670650/effects-of-vonoprazan-compared-with-esomeprazole-on-the-healing-of-artificial-postendoscopic-submucosal-dissection-ulcers-a-prospective-multicenter-two-arm-randomized-controlled-trial
#5
Yasuaki Ishii, Hiroaki Yamada, Takeshi Sato, Soichiro Sue, Hiroaki Kaneko, Kuniyasu Irie, Tomohiko Sasaki, Toshihide Tamura, Ryosuke Ikeda, Takehide Fukuchi, Ryosuke Kobayashi, Makomo Makazu, Chiko Sato, Kingo Hirasawa, Masaaki Kondo, Wataru Shibata, Shin Maeda
Background: Vonoprazan affords more clinical benefits than proton pump inhibitors (PPIs) during the healing of gastroduodenal ulcers. However, it remains controversial whether vonoprazan is more effective than PPIs when used to heal artificial ulcers arising after endoscopic submucosal dissection (ESD). Aim: This study investigated the effects of vonoprazan compared with esomeprazole on the healing of post-ESD artificial ulcers. Methods: Sixty patients who underwent gastric ESD between May 2015 and May 2017 were randomized to treatment with vonoprazan (V group) or esomeprazole (E group) for 8 weeks...
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29662293/maintenance-for-healed-erosive-esophagitis-phase-iii-comparison-of-vonoprazan-with-lansoprazole
#6
Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, Yuuichi Sakurai, Tetsuharu Hori, Kentarou Kudou, Akira Nishimura, Eiji Umegaki
AIM: To compare vonoprazan 10 and 20 mg vs lansoprazole 15 mg as maintenance therapy in healed erosive esophagitis (EE). METHODS: A total of 607 patients aged ≥ 20 years, with endoscopically-confirmed healed EE following 8 wk of treatment with vonoprazan 20 mg once daily, were randomized 1:1:1 to receive lansoprazole 15 mg ( n = 201), vonoprazan 10 mg ( n = 202), or vonoprazan 20 mg ( n = 204), once daily. The primary endpoint of the study was the rate of endoscopically-confirmed EE recurrence during a 24-wk maintenance period...
April 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29659034/embryo-fetal-toxicity-assessment-of-vonoprazan-in-rats-and-rabbits
#7
Tianyi Li, Hongqun Qiao, Peng Yue, Ming Cai, Xuejun He
Vonoprazan is a new potassium-competitive acid blocker to treat acid-related diseases. However, its safety during pregnancy is unclear. The aim of the study was to investigate the potential reproductive toxicity on the embryo-fetal development of vonoprazan. Vonoprazan acetate was administered by intravenous injection to pregnant rats (0, 2, 6 and 20 mg kg-1 day-1 ) and rabbits (0, 1.2, 3.6 and 12 mg kg-1 day-1 ) during the organogenetic period (gestation day 6-15 [rats] and 6-18 [rabbits]). Maternal reproductive endpoints were evaluated, together with effects on fetal growth and morphological development...
April 16, 2018: Journal of Applied Toxicology: JAT
https://www.readbyqxmd.com/read/29618813/crystal-structures-of-the-gastric-proton-pump
#8
Kazuhiro Abe, Katsumasa Irie, Hanayo Nakanishi, Hiroshi Suzuki, Yoshinori Fujiyoshi
The gastric proton pump-the H+ , K+ -ATPase-is a P-type ATPase responsible for acidifying the gastric juice down to pH 1. This corresponds to a million-fold proton gradient across the membrane of the parietal cell, the steepest known cation gradient of any mammalian tissue. The H+ , K+ -ATPase is an important target for drugs that treat gastric acid-related diseases. Here we present crystal structures of the H+ , K+ -ATPase in complex with two blockers, vonoprazan and SCH28080, in the luminal-open state, at 2...
April 4, 2018: Nature
https://www.readbyqxmd.com/read/29607951/efficacy-of-vonoprazan-for-gastroesophageal-reflux-symptoms-in-patients-with-proton-pump-inhibitor-resistant-non-erosive-reflux-disease
#9
Ryota Niikura, Atsuo Yamada, Yoshihiro Hirata, Yoku Hayakawa, Akihiro Takahashi, Tomohiro Shinozaki, Yoshinori Takeuchi, Mitsuhiro Fujishiro, Kazuhiko Koike
Objective Clinically, patients with proton pomp inhibitor (PPI)-resistant gastro-esophageal reflux disease (GERD) are very challenging to treat. The aim of this study was to determine the rates of symptom relief and adverse events among PPI-resistant GERD patients that changed their therapy from a PPI to vonoprazan. Methods Patients with severe gastroesophageal reflux symptoms (total GERD-Q score ≥8) without endoscopic findings of mucosal breaks who changed their medication from a PPI to vonoprazan during a 12-week period from 2015 to 2016 at 2 hospitals were selected...
March 30, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29600697/pharmacological-considerations-and-step-by-step-proposal-for-the-treatment-of-helicobacter-pylori-infection-in-the-year-2018
#10
Rinaldo Pellicano, Rocco M Zagari, Songhua Zhang, Giorgio M Saracco, Steven F Moss
Over the past 30 years, multidrug regimens consisting of a proton pump inhibitor (PPI) and two or three antibiotics have been used in treating Helicobacter pylori (H. pylori) infection. In clinical practice, the optimal regimen to cure H. pylori infection should be decided regionally. Considering the first treatment, the Maastricht V/Florence Consensus Report and the American College of Gastroenterology Clinical Management Guideline highlight that in countries with low clarithromycin resistance rates (<15%), an empiric clarithromycin-based regimen can be used...
March 30, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29581076/helicobacter-pylori-therapy-and-clinical-perspective
#11
REVIEW
Amin Talebi Bezmin Abadi, Yoshio Yamaoka
Helicobacter pylori (H. pylori) infection induces chronic gastritis and duodenal ulcer in small fraction of infected population. Three decades after introduction of the H. pylori and disclosure of urgent need for eliminating the bacterium in patients, it seems that we are still in first steps of dealing with this mysterious organism. H. pylori treatment is a complex dilemma for clinicians, a repeating sentence by many of scientists whom spend years on this research topic. Apart from many modifications in initial first-line treatment of H...
March 23, 2018: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/29527318/study-for-every-other-day-administration-of-vonoprazan-in-maintenance-treatment-of-erosive-gerd-study-protocol-for-a-multicentre-randomised-cross-over-study
#12
Mototsugu Kato, Noriko Ito, Mamiko Demura, Kimitoshi Kubo, Katsuhiro Mabe, Naohiko Harada
Introduction: The first drug selected for treatment of gastro-oesophageal reflux disease (GERD) and prevention of the recurrence is a proton pump inhibitor (PPI), but recently, a potassium-competitive acid blocker (P-CAB) was put on the market in Japan. Its onset of effect is faster than PPI, and it takes more than 2 days to recover acid secretion after the withdrawal period. Therefore, unlike PPI, the usefulness of every other day administration or discontinuous administration is expected...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29514137/efficacy-of-on-demand-therapy-using-20-mg-vonoprazan-for-mild-reflux-esophagitis
#13
Mariko Umezawa, Noriyuki Kawami, Shintaro Hoshino, Yoshimasa Hoshikawa, Eriko Koizumi, Nana Takenouchi, Yuriko Hanada, Mitsuru Kaise, Katsuhiko Iwakiri
BACKGROUND: The study aimed to evaluate the efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis (RE). METHODS: On-demand therapy by taking one 20-mg tablet of vonoprazan only when reflux symptoms occurred was performed for 24 weeks using 30 patients with mild RE who were receiving maintenance therapy with proton pomp inhibitors (PPIs). The presence or absence of RE, degree of overall satisfaction with the treatment, score of symptoms, and fasting gastrin level before breakfast were examined before and after on-demand therapy...
2018: Digestion
https://www.readbyqxmd.com/read/29464587/comparison-of-the-effects-of-vonoprazan-and-lansoprazole-for-treating-endoscopic-submucosal-dissection-induced-artificial-ulcers
#14
Ai Hirai, Toshihisa Takeuchi, Yoshiaki Takahashi, Shinpei Kawaguchi, Kazuhiro Ota, Satoshi Harada, Yuichi Kojima, Kazunari Tominaga, Satoshi Tokioka, Kazuhide Higuchi
BACKGROUND: Vonoprazan exhibits a more potent, rapid, and longer-lasting inhibitory effect on gastric acid secretion than proton pump inhibitors; however, whether it is more effective than PPI for treating endoscopic submucosal dissection (ESD)-induced artificial ulcers remains controversial. AIM: This study aimed to assess and compare the effects of vonoprazan and lansoprazole for treating ESD-induced artificial ulcers. METHODS: This prospective, randomized controlled trial enrolled 149 patients who underwent ESD for the treatment of early gastric neoplasms from April 2015 to May 2017...
April 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29435273/efficacy-of-vonoprazan-for-24-week-maintenance-therapy-of-patients-with-healed-reflux-esophagitis-refractory-to-proton-pump-inhibitors
#15
Hideki Mizuno, Kazutoshi Yamada, Keiji Minouchi, Shinji Kamiyamamoto, Yoshinobu Hinoue
The aim of the present study was to evaluate the efficacy of a potassium-competitive acid blocker (P-CAB), vonoprazan, for the maintenance therapy of healed reflux esophagitis (RE). A total of 60 patients were enrolled in this open-label, single-center, prospective study. All patients were diagnosed with RE with a frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) total score ≥8 following treatment with standard proton pump inhibitors (PPIs) for a minimum of 8 weeks. Standard PPI treatment was switched to vonoprazan 20 mg once daily for 4 weeks...
February 2018: Biomedical Reports
https://www.readbyqxmd.com/read/29416369/rationale-and-design-of-the-vision-study-a-randomized-open-label-study-to-evaluate-the-long-term-safety-of-vonoprazan-as-maintenance-treatment-in-patients-with-erosive-esophagitis
#16
Naomi Uemura, Yoshikazu Kinoshita, Ken Haruma, Takashi Yao, Ryoji Kushima, Tatsuhiro Kanoo
Erosive esophagitis (EE) occurs when the epithelial mucosa is damaged due to gastric acid reflux, and the incidence of this disease is increasing in Japan due to changes in diet and lifestyle. The condition can be treated using proton pump inhibitors (PPIs) that act by irreversibly blocking the H+ ,K+ -ATPase responsible for acid secretion. Vonoprazan is a K+ competitive channel inhibitor, which reversibly and potently inhibits gastric acid secretion. However, long-term data on vonoprazan use are limited. The aim of the VISION trial is to investigate the long-term efficacy and safety of vonoprazan in comparison with the PPI lansoprazole...
2018: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/29393198/does-the-novel-potassium-competitive-acid-blocker-vonoprazan-cause-more-hypergastrinemia-than-conventional-proton-pump-inhibitors-a-multicenter-prospective-cross-sectional-study
#17
Yuichi Kojima, Toshihisa Takeuchi, Makoto Sanomura, Ken Higashino, Keishi Kojima, Kenji Fukumoto, Kou Takata, Hiroki Sakamoto, Masahiro Sakaguchi, Kazunari Tominaga, Kazuhide Higuchi
BACKGROUND/AIM: The long-term administration of proton pump inhibitors (PPIs) is useful for preventing recurrent reflux esophagitis. On the other hand, several adverse reactions, such as an increase in the blood gastrin level, have been reported. The aim of the present study was to examine the increase in the blood gastrin level due to the long-term administration of conventional PPIs compared with vonoprazan. METHODS: A prospective cross-sectional study was conducted...
2018: Digestion
https://www.readbyqxmd.com/read/29393194/vonoprazan-a-novel-potassium-competitive-acid-blocker-should-be-used-for-the-helicobacter-pylori-eradication-therapy-as-first-choice-a-large-sample-study-of-vonoprazan-in-real-world-compared-with-our-randomized-control-trial-using-second-generation-proton-pump
#18
Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga, Kazuhide Higuchi
BACKGROUND/AIMS: Phase III study demonstrated that vonoprazan-based Helicobacter pylori eradication therapy achieved higher eradication rate compared with lansoprazole. However, there is no study that evaluated the efficacy of vonoprazan in a large sample in real world. We investigated the eradication rate and safety of vonoprazan-based eradication therapy compared with our randomized control trial using second-generation proton pump inhibitor (PPIs). METHODS: (First study) A total of 147 patients who have H...
2018: Digestion
https://www.readbyqxmd.com/read/29383028/vonoprazan-fumarate-a-novel-potassium-competitive-acid-blocker-in-the-management-of-gastroesophageal-reflux-disease-safety-and-clinical-evidence-to-date
#19
REVIEW
Kentaro Sugano
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the potassium-binding site of H+ , K+ -adenosine triphosphate (ATP)ase. Although the history of this class of drugs started over 30 years ago, clinical use of two P-CABs, revaprazan and vonoprazan, were only recently approved in Korea and Japan, respectively. Among them, vonoprazan has several advantages over conventional proton-pump inhibitors (PPIs), including rapid onset of action, long duration of acid suppression, fewer interindividual variations in terms of acid suppression, and minimum dietary influence on its action...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29337157/update-on-the-use-of-vonoprazan-a-competitive-acid-blocker
#20
EDITORIAL
David Y Graham, Maria Pina Dore
No abstract text is available yet for this article.
February 2018: Gastroenterology
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"